Key result
Aliskiren treatment for 28 days reduced blood pressure to wild-type levels and ameliorated renal interstitial fibrosis and inflammation in 10-month-old renin transgenic mice.
Why the study?
Does aliskiren reverse renal disease and cardiac hypertrophy in a transgenic mouse model of hypertensive chronic kidney disease?
Does aliskiren reverse renal disease and cardiac hypertrophy in a transgenic mouse model of hypertensive chronic kidney disease?
Direct renin inhibition with aliskiren reverses renal fibrosis and cardiac hypertrophy in a hypertensive mouse model, demonstrating nephroprotective effects independent of blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Preclinical data in renin transgenic mice are hypothesis-generating; leaves open whether aliskiren reverses renal fibrosis in human hypertensive CKD.
Aliskiren, a direct renin inhibitor, is a novel antihypertensive drug. To study whether aliskiren can reverse chronic kidney disease, we administered it to renin transgenic mice, a strain characterized by elevated blood pressure and a slow decline of renal function, mimicking well the progression of hypertensive chronic kidney disease. Ten-month-old transgenic mice were treated either with aliskiren or placebo for 28 days. Age-matched wild-type mice treated or not with aliskiren were considered as normotensive controls. Aliskiren reduced blood pressure to wild-type levels from as early as day 14. Proteinuria and cardiac hypertrophy and fibrosis were also normalized. Renal interstitial fibrosis and inflammation were significantly ameliorated in aliskiren-treated mice (shown by the decrease of proinflammatory and profibrotic markers), and the phenotypes of tubular epithelial cells and podocytes were restored as evidenced by the reappearance of cellular proteins characteristic of normal phenotype of these cells. Profibrotic p38 and Erk mitogen-activated protein kinases were highly activated in placebo-treated transgenic animals. Aliskiren treatment cancelled this activation. This nephroprotection was not attributed to the antihypertensive activity of aliskiren, because blood pressure normalization after treatment with hydralazine failed to induce the regression of renal fibrosis. Direct inhibition of renin can restore renal function and structure in aged hypertensive animals with existing proteinuria. This finding suggests that, in addition to antihypertensive action, aliskiren can be also used to treat chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Kavvadas et al. (2013) studied Hypertensive chronic kidney disease. Aliskiren vs. Placebo was evaluated on Blood pressure, proteinuria, cardiac hypertrophy, and renal fibrosis. Aliskiren treatment for 28 days reduced blood pressure to wild-type levels and ameliorated renal interstitial fibrosis and inflammation in 10-month-old renin transgenic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: